151 results on '"Boumpas, Dimitrios T"'
Search Results
2. Multicriteria decision analysis process to develop new classification criteria for systemic lupus erythematosus
3. Management of systemic lupus erythematosus: a systematic literature review informing the 2023 update of the EULAR recommendations.
4. Disentangling the riddle of systemic lupus erythematosus with antiphospholipid syndrome: blood transcriptome analysis reveals a less-pronounced IFN- signature and distinct molecular profiles in venous versus arterial events.
5. Pragmatic targets for moderate/severe SLE and their implications for clinical care and trial design: sustained DORIS or LLDAS for at least 6 months is sufficient while their attainment for at least 24 months ensures high specificity for damage-free progression
6. EULAR recommendations for the management of systemic lupus erythematosus: 2023 update
7. Annals of the Rheumatic Diseases collection on lupus nephritis (2019–2022): novel insights and advances in therapy
8. Microglia activation in the presence of intact blood–brain barrier and disruption of hippocampal neurogenesis via IL-6 and IL-18 mediate early diffuse neuropsychiatric lupus
9. 2022 EULAR points to consider for the measurement, reporting and application of IFN-I pathway activation assays in clinical research and practice
10. Unmet need in rheumatology: reports from the Advances in Targeted Therapies meeting, 2022
11. Epidemiology and burden of systemic lupus erythematosus in a Southern European population: data from the community-based lupus registry of Crete, Greece
12. 05.14 Rna-seq profiling of hematopoietic stem cells in murine systemic lupus erythematosus (sle): validation and functional characterisation
13. Cross-species transcriptome analysis for early detection and specific therapeutic targeting of human lupus nephritis
14. EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome
15. Treatment of lupus: more options after a long wait
16. Neutrophil extracellular traps regulate IL-1β-mediated inflammation in familial Mediterranean fever
17. Tissue factor expression in neutrophil extracellular traps and neutrophil derived microparticles in antineutrophil cytoplasmic antibody associated vasculitis may promote thromboinflammation and the thrombophilic state associated with the disease
18. Response to: Correspondence on “Update on the diagnosis and management of systemic lupus erythematosus” by Zhouet al
19. Quality indicators for systemic lupus erythematosus based on the 2019 EULAR recommendations: development and initial validation in a cohort of 220 patients
20. Response to: Correspondence on 'EULAR recommendations for the management of systemic lupus erythematosus: 2023 update' by Fanouriakis et al.
21. Lupus or not? SLE Risk Probability Index (SLERPI): a simple, clinician-friendly machine learning-based model to assist the diagnosis of systemic lupus erythematosus
22. European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) SLE classification criteria item performance
23. Update οn the diagnosis and management of systemic lupus erythematosus
24. Performance of the 2019 EULAR/ACR classification criteria for systemic lupus erythematosus in early disease, across sexes and ethnicities
25. Response to: ‘Hydroxychloroquine is neutral in risk of chronic kidney disease in patients with systemic lupus erythematosus’ by Wuet al
26. Population-based studies in systemic lupus erythematosus: immune thrombocytopenic purpura or ‘blood-dominant’ lupus?
27. 2019 Update of the Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA–EDTA) recommendations for the management of lupus nephritis
28. Therapeutic opportunities in systemic lupus erythematosus: state of the art and prospects for the new decade
29. Investigation of potential non-HLA rheumatoid arthritis susceptibility loci in a European cohort increases the evidence for nine markers
30. The TRAF1-C5 region on chromosome 9q33 is associated with multiple autoimmune diseases
31. Evidence for treating rheumatoid arthritis to target: results of a systematic literature search
32. Transcriptome reprogramming and myeloid skewing in haematopoietic stem and progenitor cells in systemic lupus erythematosus
33. In an early SLE cohort the ACR-1997, SLICC-2012 and EULAR/ACR-2019 criteria classify non-overlapping groups of patients: use of all three criteria ensures optimal capture for clinical studies while their modification earlier classification and treatment
34. 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus
35. Response to: ‘Bone health, an often forgotten comorbidity in systemic lupus erythematosus: a comment on the new recommendations’ by Orsolini et al
36. Response to: ‘Treatment of systemic lupus erythematosus: don’t forget hydroxychloroquine’ by Michaud et al
37. Response to: ‘Concerns about the operational definition of remission in 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus’ by Rua-Figueroa and Erausquin
38. Hydroxychloroquine dosing in systemic lupus erythematosus: response to ‘Comment on the 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus by Fanouriakis et al’ by Costedoat-Chalumeau et al
39. Chloroquine as alternative antimalarial in systemic lupus erythematosus. Response to ‘2019 update of the EULAR recommendations for the management of SLE: don’t forget chloroquine’ by Figueroa-Parra et al
40. Combined genetic and transcriptome analysis of patients with SLE: distinct, targetable signatures for susceptibility and severity
41. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus
42. A decade of mycophenolate mofetil for lupus nephritis: is the glass half-empty or half-full?
43. Update οn the diagnosis and management of systemic lupus erythematosus.
44. REDD1/autophagy pathway promotes thromboinflammation and fibrosis in human systemic lupus erythematosus (SLE) through NETs decorated with tissue factor (TF) and interleukin-17A (IL-17A)
45. 2008–2018: a decade of recommendations for systemic lupus erythematosus
46. Response to: ’Neuropsychiatric lupus or not? Cerebral hypoperfusion by perfusion-weighted MRI in normal-appearing white matter in primary neuropsychiatric lupus erythematosus' by Papadakiet al'by Wallace
47. Neuropsychiatric lupus or not? Cerebral hypoperfusion by perfusion-weighted MRI in normal-appearing white matter in primary neuropsychiatric lupus erythematosus
48. Transcriptome reprogramming and myeloid skewing in haematopoietic stem and progenitor cells in systemic lupus erythematosus.
49. In an early SLE cohort the ACR-1997, SLICC-2012 and EULAR/ACR-2019 criteria classify non-overlapping groups of patients: use of all three criteria ensures optimal capture for clinical studies while their modification earlier classification and treatment.
50. REDD1/autophagy pathway promotes thromboinflammation and fibrosis in human systemic lupus erythematosus (SLE) through NETs decorated with tissue factor (TF) and interleukin-17A (IL-17A).
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.